334 related articles for article (PubMed ID: 23315099)
1. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
3. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Pancreas; 2014 Apr; 43(3):411-6. PubMed ID: 24622071
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Boeck S; Wittwer C; Heinemann V; Haas M; Kern C; Stieber P; Nagel D; Holdenrieder S
Br J Cancer; 2013 Apr; 108(8):1684-94. PubMed ID: 23579210
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
6. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
[TBL] [Abstract][Full Text] [Related]
7. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
8. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
[TBL] [Abstract][Full Text] [Related]
11. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy.
Guo G; Chen X; Cai X; Chen Y; Wang H; Fan L; Bai L; Qiu H; Zhang B
Transl Cancer Res; 2019 Aug; 8(4):1137-1147. PubMed ID: 35116856
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.
Giessen-Jung C; Nagel D; Glas M; Spelsberg F; Lau-Werner U; Modest DP; Schulz C; Heinemann V; Di Gioia D; Stieber P
Tumour Biol; 2015 Sep; 36(10):7897-906. PubMed ID: 25953265
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study.
Imaoka H; Mizuno N; Hara K; Hijioka S; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Hieda N; Yoshida T; Okuno N; Shimizu Y; Niwa Y; Yamao K
Pancreatology; 2016; 16(5):859-64. PubMed ID: 27256641
[TBL] [Abstract][Full Text] [Related]
15. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
16. Can Albumin Bilirubin Ratio and Inflammatory Prognostic Index Be A New Marker Determining Survival in Metastatic Pancreatic Cancer?
Ekinci F; Sarı D; Çelik C; Dirican A; Erdoğan AP; Gökse G
Gulf J Oncolog; 2021 May; 1(36):45-52. PubMed ID: 35017135
[TBL] [Abstract][Full Text] [Related]
17. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer.
Ma YY; Wang H; Zhao WD; Li YF; Wang JJ; Chen XY; Huang YQ; Wang WJ; Wang Y; Sun SC
Cancer Control; 2022; 29():10732748211053150. PubMed ID: 34989251
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
